See the DrugPatentWatch profile for Entresto
Entresto was approved by the U.S. Food and Drug Administration (FDA) on July 7, 2015 [1].
What is Entresto used for?
Entresto, also known by its generic name sacubitril/valsartan, is prescribed to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with symptomatic chronic heart failure with reduced ejection fraction [1].
How does Entresto work?
Entresto combines a neprilysin inhibitor (sacubitril) and an angiotensin II receptor blocker (valsartan) [1]. Sacubitril increases the levels of natriuretic peptides, which help reduce strain on the heart and lower blood pressure. Valsartan blocks the effects of angiotensin II, a hormone that narrows blood vessels and increases blood pressure [1].
When does Entresto patent protection expire?
Patent protection timelines for medications can be complex, involving multiple patents with varying expiry dates. Information on Entresto's specific patent expiry dates can be found through resources that track drug patents [2].
Who manufactures Entresto?
Entresto is manufactured by Novartis [3].
What are the alternatives to Entresto for heart failure?
Other medications used to treat heart failure with reduced ejection fraction include ACE inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors [4]. The choice of treatment depends on individual patient factors and physician recommendations.
What are common side effects of Entresto?
Common side effects of Entresto include low blood pressure, high potassium levels, dizziness, cough, and kidney problems [1]. Patients are advised to report any side effects to their healthcare provider.